Edition:
United Kingdom

Luye Pharma Group Ltd (2186.HK)

2186.HK on Hong Kong Stock

8.39HKD
19 Apr 2018
Change (% chg)

-- (--)
Prev Close
HK$8.39
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
26,596,217
52-wk High
HK$9.75
52-wk Low
HK$3.95

Chart for

About

Luye Pharma Group Ltd. is an investment holding company principally engaged in the development, production, marketing and sale of pharmaceutical products. Along with subsidiaries, the Company operates its business through four segments: the Oncology Drugs segment, the Cardiovascular System Drugs segment, the Alimentary Tract and... (more)

Overall

Beta: --
Market Cap(Mil.): HK$15,675.47
Shares Outstanding(Mil.): 3,321.07
Dividend: --
Yield (%): --

Financials

  2186.HK Industry Sector
P/E (TTM): 15.59 30.95 32.74
EPS (TTM): 0.30 -- --
ROI: 13.25 14.84 14.38
ROE: 13.61 16.34 16.07

BRIEF-Luye Pharma Group Says LY03003 Drug Approved To Proceed To Phase III Clinical Trials In China

* LY03003 OBTAINED APPROVAL FROM CHINA FOOD AND DRUG ADMINISTRATION TO PROCEED TO PHASE III CLINICAL TRIALS IN CHINA Source text for Eikon: Further company coverage:

10 Apr 2018

BRIEF-Luye Pharma Group Posts FY Profit Attributable Of RMB981.4 Million​

* ‍FY PROFIT ATTRIBUTABLE ROSE 10.1% TO RMB981.4 MILLION​ Source text for Eikon: Further company coverage:

26 Mar 2018

BRIEF-Luye Pharma Group Announces collaboration With Excel Biopharma

* Immuno-Oncology Antibody Drug Development Collaboration With Excel Biopharm

21 Mar 2018

BRIEF-Luye Pharma Group Says ‍Rotigotine Exempted From Phase 2 Dosage Exploration Clinical Trials​

* ‍ROTIGOTINE EXTENDED RELEASE MICROSPHERES FOR INJECTION IS EXEMPTED FROM PHASE II DOSAGE EXPLORATION CLINICAL TRIALS​ Source text for Eikon: Further company coverage:

12 Mar 2018

BRIEF-Luye Pharma Group Says ‍CFDA Accepted Clinical Trial Application For Co's Anti-Tumor Drug

* ‍CFDA OFFICIALLY ACCEPTED CLINICAL TRIAL APPLICATION FOR ANTI-TUMOR DRUG Source text for Eikon: Further company coverage:

26 Feb 2018

BRIEF-Luye Pharma Group Says FDA To Waive Pediatric Clinical Trials Of Schizophrenia Drug

* FDA AGREES TO WAIVE PEDIATRIC CLINICAL TRIALS OF SCHIZOPHRENIA DRUG LY03004

21 Feb 2018

BRIEF-Luye Pharma Group's Drug Approved By U.S. FDA

* ‍GROUP'S DRUG ROTIGOTINE EXTENDED RELEASE MICROSPHERES FOR INJECTION HAS BEEN APPROVED BY U.S. FDA

08 Feb 2018

BRIEF-Luye Pharma ‍Updates On Development Of Ansofaxine Hydrochloride Extended Release Tablets​

* ‍UPDATES ON PHASE II CLINICAL TRIAL IN CHINA FOR ANSOFAXINE HYDROCHLORIDE EXTENDED RELEASE TABLETS​

23 Jan 2018

BRIEF-Luye Pharma Group‍ Announces Update on Patent Litigation Regarding Rivastigmine 1 Day Patch

* COURT OF APPEAL FOR DISTRICT OF MUNICH, GERMANY DISMISSES APPEAL FROM NOVARTIS AG AS CLAIMANT IN PATENT INFRINGEMENT LAWSUIT

28 Dec 2017

BRIEF-Luye Pharma Says ‍Unit Applies To Register For Proposed Issue Of Debt Securities

* ‍UNIT APPLIES TO NATIONAL ASSOCIATION OF FINANCIAL MARKET INSTITUTIONAL INVESTORS TO REGISTER FOR PROPOSED ISSUE OF DEBT SECURITIES

19 Dec 2017

Earnings vs. Estimates